Сравнение
Cagrilintide vs. Mazdutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
1415456-99-3
2259884-03-0
Молекулярная масса
4253.7 g/mol
4790 g/mol
Период полувыведения
168 h
132 h
Последовательность
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYsynthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteМеханизм действия
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
4
из них на людях
3
4
Зафиксированные эффекты
3
4
Открытые противоречия
1
0
Задокументированные нежелательные явления
1
0
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Cagrilintide and Mazdutide?
- Cagrilintide is classified as "Метаболизм", while Mazdutide is classified as "Метаболизм". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Mazdutide?
- The highest available evidence level is "РКИ на людях" for Cagrilintide and "РКИ на людях" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Mazdutide in Germany and the United States?
- Германия: Cagrilintide — Не одобрено, Mazdutide — Только для исследований. США: Cagrilintide — Не одобрено, Mazdutide — Только для исследований. These are factual summaries with source and review date on the individual pages.